Journal
EMERGING INFECTIOUS DISEASES
Volume 17, Issue 10, Pages 1855-1864Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid1710.110087
Keywords
-
Categories
Funding
- Centers for Disease Control and Prevention [5U01CI000286-05]
- Merck Co., Inc.
- Astellas U.S., Inc.
- Pfizer, Inc.
- Schering-Plough Research Institute
- Enzon Pharmaceuticals, Inc.
Ask authors/readers for more resources
Recent reports describe increasing incidence of non-Aspergillus mold infections in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients. To investigate the epidemiology of infections with Mucorales, Fusarium spp., and Scedosporium spp. molds, we analyzed data from the Transplant-Associated Infection Surveillance Network, 23 transplant centers that conducted prospective surveillance for invasive fungal infections during 2001-2006. We identified 169 infections (105 Mucorales, 37 Fusarium spp., and 27 Scedosporium spp.) in 169 patients; 124 (73.4%) were in HCT recipients, and 45 (26.6%) were in SOT recipients. The crude 90-day mortality rate was 56.6%. The 12-month mucormycosis cumulative incidence was 0.29% for HCT and 0.07% for SOT. Mucormycosis incidence among HCT recipients varied widely, from 0.08% to 0.69%, with higher incidence in cohorts receiving transplants during 2003 and 2004. Non-Aspergillus mold infections continue to be associated with high mortality rates. The incidence of mucormycosis in HOT recipients increased substantially during the surveillance period.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available